B lymphocytes are regulated by multiple environmental stimuli produced during the immune response. Each of these signals may act on different subpopulations of B lymphocytes and/or select responding B cells for particular functions. My laboratory has identified a cDNA for a novel cytokine we call HMW-BCGF (high molecular weight-B cell growth factor). HMW-BCGF induces proliferation and inhibits immunoglobulin secretion by activated human B lymphocytes. Studies using highly purified HMW-BCGF and monoclonal antibodies to both HMW-BCGF and its receptor suggest that this lymphokine plays a role in expanding a subpopulation of memory B cells. Our work in the last two years has revealed that more than one form of HMW-BCGF may exist. We propose to optimize production of recombinant pI 7.8-HMW-BCGF, to examine whether recombinant HMW-BCGF has all the activities we have previously identified for native HMW-BCGF, to analyze the binding of recombinant HMW-BCGF to activated B cells, as well as to cells of other lineages, and to develop a panel of monoclonal antibodies recognizing different epitopes of HMW-BCGF. We will use probes based on the pI 7.8-HMW-BCGF cDNA to examine when HMW- BCGF production occurs in mononuclear cells stimulated in vitro with antigen or mitogens, where HMW-BCGF production occurs in normal human tonsils and spleen, and whether HMW-BCGF production occurs in any normal B cell subpopulations. Finally, we will use monoclonal antibodies and deletion mutants of pI 7.8-HMW-BCGF to determine which portions of the molecule are necessary for binding to B cells and for induction of different B cell functions. These studies will provide new insight into the regulation of human B cell proliferation by HMW-BCGF. They may suggest potential therapeutic uses for HMW-BCGF.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI030030-01A3
Application #
3145091
Study Section
Experimental Immunology Study Section (EI)
Project Start
1993-05-15
Project End
1996-04-30
Budget Start
1993-05-15
Budget End
1994-04-30
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Barnes-Jewish Hospital
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63110
Dey, Antu K; David, Kathryn B; Ray, Neelanjana et al. (2008) N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology 372:187-200
Shan, Meimei; Klasse, Per Johan; Banerjee, Kaustuv et al. (2007) HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog 3:e169
Herrera, Carolina; Klasse, Per Johan; Kibler, Christopher W et al. (2006) Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex. Virology 351:121-32
Beddows, Simon; Kirschner, Marc; Campbell-Gardener, Lila et al. (2006) Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A. AIDS Res Hum Retroviruses 22:569-79
Kirschner, Marc; Monrose, Val; Paluch, Maciej et al. (2006) The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr Purif 48:61-8
Herrera, Carolina; Klasse, Per Johan; Michael, Elizabeth et al. (2005) The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 338:154-72
Hartley, Oliver; Klasse, Per Johan; Sattentau, Quentin J et al. (2005) V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 21:171-89
Beddows, Simon; Schulke, Norbert; Kirschner, Marc et al. (2005) Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 79:8812-27